DOI QR코드

DOI QR Code

The Interleukin-18 Promoter -607C>A Polymorphism Contributes to Nasopharyngeal Carcinoma Risk: Evidence from a Meta-analysis Including 1,886 Subjects

  • Guo, Xu-Guang (Department of Clinical Laboratory Medicine, the Third affiliated Hospital of Guangzhou Medical University) ;
  • Xia, Yong (Department of Clinical Laboratory Medicine, the Third affiliated Hospital of Guangzhou Medical University)
  • Published : 2013.12.31

Abstract

The interleukin-18 promoter -607C>A gene polymorphism may be related to nasopharyngeal carcinoma (NPC) risk but the results of individual studies remain conflicting. A meta-analysis including 1,886 subjects from five individual studies was therefore performed to provide a more accurate estimation. Pooled odds ratios (ORs) and their corresponding 95% confidence intervals (95% CIs) were evaluated by fixed- or random-effects models. A significant relationship between interleukin-18 promoter -607C>A gene polymorphism and NPC was found in a dominant genetic model (OR: 1.351, 95% CI: 1.089-1.676, P=0.006, $P_{heterogeneity}$=0.904), a homozygote model (OR: 1.338, 95% CI: 1.023-1.751, P=0.034, $P_{heterogeneity}$=0.863), and a heterozygote model (OR: 1.357, 95% CI: 1.080-1.704, P=0.009, $P_{heterogeneity}$=0.824). No significant association was detected in either an allelic genetic model (OR: 1.077, 95% CI: 0.960-1.207, 0.207, $P_{heterogeneity}$=0.844) or a recessive genetic model (OR: 1.093, 95% CI: 0.878-1.361, P=0.425, $P_{heterogeneity}$=0.707). In conclusion, a significant association was found between interleukin-18 promoter -607C>A gene polymorphism and NPC risk. Individuals with the C allele of interleukin-18 promoter -607C>A gene polymorphism have a higher risk of NPC development.

References

  1. Bombardieri M, McInnes IB, Pitzalis C (2007). Interleukin-18 as a potential therapeutic target in chronic autoimmune/inflammatory conditions. Expert Opin Biol Th, 7, 31-40. https://doi.org/10.1517/14712598.7.1.31
  2. Chan AT, Teo PM, Johnson PJ (2002). Nasopharyngeal carcinoma. Ann Oncol, 13, 1007-15. https://doi.org/10.1093/annonc/mdf179
  3. Cochran WG (1968). The effectiveness of adjustment by subclassification in removing bias in observational studies. Biometrics, 24, 295-313. https://doi.org/10.2307/2528036
  4. DeSantis C, Naishadham D, Jemal A (2013). Cancer statistics for African Americans, 2013. CA-Cancer J Clin, 63,151-66. https://doi.org/10.3322/caac.21173
  5. Dinarello CA, Novick D, Kim S, Kaplanski G (2013). Interleukin-18 and IL-18 Binding Protein. Front Immunol, 4, 289.
  6. Du B, Zhao J, Wei Y (2012). Interleukin-18 gene genetic polymorphisms and risk Of nasopharyngeal carcinoma in Han population from Sichuan China. Med J West China, 25, 1683-6.
  7. Egger M, Smith G, Schneider M, Minder C. (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  8. Farhat K, Hassen E, Bouzgarrou N, et al (2008). Functional IL-18 promoter gene polymorphisms in Tunisian nasopharyngeal carcinoma patients. Cytokine, 43, 132-7. https://doi.org/10.1016/j.cyto.2008.05.004
  9. Fariasa TD, Canto LM, Medeiros MD, et al (2013). Lack of association between interleukin-18 polymorphisms and rheumatoid arthritis. Rev Bras Reumatol, 53, 199-205. https://doi.org/10.1590/S0482-50042013000200007
  10. Jemal A, Bray F, Center MM, et al (2011). Global Cancer Statistics. CA-Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  11. Ji J, Lee W (2013). Interleukin-18 gene polymorphisms and rheumatoid arthritis: A meta-analysis. Gene, 523, 27-32. https://doi.org/10.1016/j.gene.2013.03.132
  12. Ma Y, Zhang B, Tang R, et al (2012). Interleukin-18 promoter polymorphism and asthma risk: a meta-analysis. Mol Biol Rep, 39, 1371-6. https://doi.org/10.1007/s11033-011-0871-6
  13. Mantel N, Haensze W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer I, 22, 719-48.
  14. Mi Y, Yu Q, Yu M, et al (2011). Review and pooled analysis of studies on -607 (C/A) and -137 (G/C) polymorphisms in IL-18 and cancer risk. Med Oncol, 28, 1107-15. https://doi.org/10.1007/s12032-010-9569-1
  15. Nong L, Luo B, Zhang L, Nong H (2009). Interleukin-18 gene promoter polymorphism and the risk of nasopharyngeal carcinoma in a Chinese population. DNA Cell Biol, 28, 507-13. https://doi.org/10.1089/dna.2009.0912
  16. Pan G, Luo B, Teng Y, Liang L (2013). Research on interleukin-18 gene promotoe polymorphisms and genetic susceptibility of nasopharngeal carcinoma. Lab Med, 28, 457-61.
  17. Pratesi C, Bortolin MT, Bidoli E, et al (2006). Interleukin-10 and interleukin-18 promoter polymorphisms in an Italian cohort of patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Immunol Immun, 55,23-30. https://doi.org/10.1007/s00262-005-0688-z
  18. Song G, Bae S, Kim J, Lee Y (2013). Interleukin-4, interleukin-4 receptor, and interleukin-18 polymorphisms and rheumatoid arthritis: a meta-analysis. Immunol Invest, 42, 455-69. https://doi.org/10.3109/08820139.2013.804084
  19. Song G, Choi S, Ji J, Lee Y (2013). Association between interleukin-18 polymorphisms and systemic lupus erythematosus: a meta-analysis. Mol Biol Rep, 40, 2581-7. https://doi.org/10.1007/s11033-012-2344-y
  20. Srivastava S, Salim N, and Robertson MJ (2010). Interleukin-18: Biology and Role in the Immunotherapy of Cancer. Curr Med Chem, 17, 3353-7. https://doi.org/10.2174/092986710793176348
  21. Stuck AE, Rubenstein LZ, and Wieland D (1998). Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ, 316, 469 https://doi.org/10.1136/bmj.316.7129.469
  22. Thakkinstian A, McElduff P, Este C, et al (2005). A method for meta-analysis of molecular association studies. Stat Med, 24, 1291-306. https://doi.org/10.1002/sim.2010
  23. Wang M, Zhu X, Wang L, Lin Y (2013). The -607C/A Polymorphisms in Interleukin-18 Gene Promoter Contributes to Cancer Risk: Evidence from A Meta-Analysis of 22 Case-Control Studies. Plos One, 8, e76915. https://doi.org/10.1371/journal.pone.0076915
  24. Yang X, Qiu M, Hu J, et al (2013). Association of interleukin-18 gene promoter -607 C>A and -137G>C polymorphisms with cancer risk: a meta-analysis of 26 studies. Plos One, 8, e73671. https://doi.org/10.1371/journal.pone.0073671
  25. Yang Y, Chang T, Chen T, et al (2013). Genetic variants in interleukin-18 gene and risk for cervical squamous cell carcinoma. Hum Immunol, 74, 882-7. https://doi.org/10.1016/j.humimm.2013.04.001

Cited by

  1. The AURKA Gene rs2273535 Polymorphism Contributes to Breast Carcinoma Risk - Meta-analysis of Eleven Studies vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6709
  2. Five miRNAs as Novel Diagnostic Biomarker Candidates for Primary Nasopharyngeal Carcinoma vol.15, pp.18, 2014, https://doi.org/10.7314/APJCP.2014.15.18.7575
  3. Functional polymorphisms of interleukin-18 gene and risk of breast cancer in a Brazilian population vol.84, pp.2, 2014, https://doi.org/10.1111/tan.12367
  4. Semi-Quantitative Exposure Assessment of Occupational Exposure to Wood Dust and Nasopharyngeal Cancer Risk vol.16, pp.10, 2015, https://doi.org/10.7314/APJCP.2015.16.10.4339
  5. Interleukin-18 in Health and Disease vol.20, pp.3, 2019, https://doi.org/10.3390/ijms20030649